Influence of the progression of cryptococcal meningitis on brain penetration and efficacy of AmBisome in a murine model

Chemotherapy

Volumn 52, Issue 6, 2006, Pages 271-278

  Takemoto, K ^a   Yamamoto, Y ^a   Ueda, Y ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Amphotericin B deoxycholate; Brain penetration and localization; Cryptococcus neoformans; Liposomal amphotericin B

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; GLUCOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INFECTION; BRAIN TISSUE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DISEASE COURSE; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; FUNGAL DETECTION; FUNGAL MENINGITIS; IMMUNOHISTOCHEMISTRY; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBARACHNOID SPACE;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; BIOLOGICAL MARKERS; BRAIN; CRYPTOCOCCUS NEOFORMANS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; IMMUNOHISTOCHEMISTRY; MALE; MAXIMUM TOLERATED DOSE; MENINGITIS, CRYPTOCOCCAL; MICE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33750250286     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095820     Document Type: Article

References (30)

1. Kwon-Chung KJ, Bennett JE: Cryptococcosis; in Kwon-Chung KJ, Bennett JE (eds): Medical Mycology. London, Lea & Febiger, 1992, pp 397-446.
2. Casadevall A, Perfect JR: Cryptococcus neoformans. Washington, American Society for Microbiology Press, 1998.
3. Darras-Joly C, Chevret S, Wolff M, Matheron S, Longuet P, Casalino E, Joly V, Chochillon C, Bedos JP: Cryptococcus neoformans infection in France: epidemiologic features of and early prognostic parameters for 76 patients who were infected with human immunodeficiency virus. Clin Infect Dis 1996;23:369-376.
4. Robinson PA, Bauer M, Leal MA, Evans SG, Holtom PD, Diamond DA, Leedom JM, Larsen RA: Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999;28:82-92.
5. Mwaba P, Mwansa J, Chintu C, Pobee J, Scarborough M, Portsmouth S, Zumla A: Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J 2001;77:769-773.
6. Pitisuttithum P, Tansuphasawadikul S, Simpson AJ, Howe PA, White NJ: A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B. J Infect 2001;43:226-233.
7. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE: Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000;30:710-718.
8. Groll AH, Piscitelli SC, Walsh TJ: Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998;44:343-500.
9. Balazsovits J, Falk R: Liposomes - a novel mode of drug delivery. On Contin Pract 1988;15:25-27.
10. Papastamelos AG, Tunkel AR: Antibacterial agents in infections of the central nervous system and eye. Infect Dis Clin North Am 1995;9:615-637.
11. Lopez-Berestein G, Rosenblum MG, Mehta R: Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv 1984; 1:199-205.
12. Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, Hoy J, Borleffs JC, Allworth T, Kauffmann RH, Jones P, Kroon FP, Verbrugh HA, de Marie S: Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997;11:1463-1471.
13. Hamill RJ, Sobel J, El-Sadr W, Johnson P, Graybill JR, Javaly K, Barker D: Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients. Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999, abstract No. 1161.
14. Wei H, Hai W, Wanqing L: Clinical study on liposomal amphotericin B (AmBisome) in deep fungal infections in China. Mycoses 2003;46:24-28.
15. Takemoto K, Yamamoto Y, Ueda Y, Sumita Y, Yoshida K, Niki Y: Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis. J Antimicrob Chemother 2004;53:311-317.
16. National Committee for Clinical Laboratory Standards: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard M27-A. Wayne, National Committee for Clinical Laboratory Standards, 1997.
17. Carrillo-Muñoz AJ, Quindos G, Tur C, Ruesga M, Alonso R, del Valle O, Rodriguez V, Arévalo MP, Salgado J, Martin-Mazuelos E, Bornay-Llinares FJ, del Palacio A, Cuétara M, Gasser I, Hernández-Molina JM, Pemán J: Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole. Chemotherapy 2000;46: 235-244.
18. Jessup C, Reyes G, Fothergill A, McCarthy D, Rinaldi M, Messer S, Pfaller M, Ghannoum M: A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: a multicenter study. J Chemother 2000;12:22-29.
19. Albert MM, Stahl-Carroll TL, Luther MF, Graybill JR: Comparison of liposomal amphotericin B to amphotericin B for treatment of murine cryptococcal meningitis. J Mycol Med 1995;5:1-6.
20. Craven PC, Graybill JR: Combination of oral flucytosine and ketoconazole as therapy for experimental cryptococcal meningitis. J Infect Dis 1984;149:584-590.
21. Gondal JA, Swartz RP, Rahman A: Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother 1989;33:1544-1548.
22. Shirley E: A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. Biometrics 1977; 33:386-389.
23. Williams DA: A note on Shirley's nonparametric test for comparing several dose levels with a zero-dose control. Biometrics 1986; 42:183-186.
24. Hupe JM, James AC, Girard P, Bullier J: Response modulations by static texture surround in area V1 of the macaque monkey do not depend on feedback connections from V2. J Neurophysiol 2001;85:146-163.
25. Steel RGD: A multiple comparison rank sum test: treatments versus control. Biometrics 1959;15:560-572.
26. Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, Piscitelli SC, Walsh TJ: Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000; 182:274-282.
27. Ding JC, Bauer M, Diamond DM, Leal MA, Johnson D, Williams BK, Thomas AM, Najvar L, Graybill JR, Larsen RA: Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob Agents Chemother 1997;41:1589-1593.
28. Lortholary O, Nicolas M, Soreda S, Improvisi L, Ronin O, Petitjean O, Dupont B, Tod M, Dromer F: Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing. J Antimicrob Chemother 1999;43:817-824.
29. Bafeltowska JJ, Buszman E: Pharmacokinetics of fluconazole in the cerebrospinal fluid of children with hydrocephalus. Chemotherapy 2005;51:370-376.
30. Clemons KV, Stevens DA: Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob Agents Chemother 1998;42:899-902.